SCHEMBL3797261

SCHEMBL3797261

CCOC(=O)CCN1Cc2cc(N)ccc2C1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 4/20 0.58
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 3/20 0.44
TSHR P16473 2/20 0.44
SIRT1 Q96EB6 1/20 0.44
ITGB3 P05106 1/20 0.43
ITGAV P06756 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
AOC3 Q16853 4/20 0.41
PIN1 Q13526 1/20 0.40
PIN4 Q9Y237 1/20 0.40
MAPT P10636 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HDAC6 Q9UBN7 1/20 0.39
KAT2B Q92831 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180564 0.85 TNF (0.45) TNFKDM4EALDH1A1ALOX15TSHR
SCHEMBL3797765 0.81 MAPT (0.47) TNFKDM4EALDH1A1ALOX15TSHR
SCHEMBL7327411 0.81 TNF (0.54) TNFKDM4EALDH1A1HPGDALOX15
SCHEMBL4724309 0.80 KDM4E (0.48) TNFKDM4EALDH1A1HPGDALOX15
SCHEMBL6446130 0.78 TNF (0.46) TNFKDM4EALOX15PIN1PIN4
SCHEMBL6450587 0.78 TNF (0.46) TNFKDM4EALOX15PIN1PIN4
SCHEMBL2504791 0.78 KDM4E (0.52) TNFKDM4EALDH1A1HPGDALOX15
SCHEMBL3388515 0.77 KDM4E (0.51) TNFKDM4EALDH1A1HPGDALOX15
SCHEMBL1950557 0.77 ATAD2 (0.45) TNFKDM4EALDH1A1HPGDALOX15
SCHEMBL1468030 0.77 TNF (0.49) TNFALOX15MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064545-B1 METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS PIRAMAL LIFE SCIENCES LTD (IN) 2012-07-04 EP disclosed
EP-2256496-A2 Method for identifying compounds that act as insulin-sensitizers Piramal Life Sciences Limited (IN) 2010-12-01 EP disclosed
US-20090318465-A1 METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS Piramal Enterprises Limited (IN) 2009-12-24 US disclosed
EP-2064545-A2 METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS Piramal Life Sciences Limited (IN) 2009-06-03 EP disclosed
WO-2008035309-A2 METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS PIRAMAL LIFE SCIENCES LIMITED (IN) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318465-A1 METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS GPR119, SLC2A4, INSR TNF 3187/4885KDM4E 3621/4885ALDH1A1 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.